122 related articles for article (PubMed ID: 9658720)
1. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
Catani L; Gugliotta L; Motta M; Tazzari P; Baravelli S; Tura S
Haematologica; 1998 May; 83(5):385-91. PubMed ID: 9658720
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
3. Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
Shibuya K; Kuwaki T; Akahori H; Kato T; Miyazaki H
Leuk Res; 2004 Sep; 28(9):941-6. PubMed ID: 15234571
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
[TBL] [Abstract][Full Text] [Related]
6. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
7. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
Basser RL
Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
9. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
10. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
Adams JA; Liu Yin JA; Brereton ML; Briggs M; Burgess R; Hyde K
Br J Haematol; 1997 Oct; 99(1):139-46. PubMed ID: 9359514
[TBL] [Abstract][Full Text] [Related]
11. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
12. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
13. Expression of protease activated receptor 3 (PAR3) is upregulated by induction of megakaryocyte phenotype in human erythroleukemia (HEL) cells.
Cupit LD; Schmidt VA; Gnatenko DV; Bahou WF
Exp Hematol; 2004 Oct; 32(10):991-9. PubMed ID: 15504554
[TBL] [Abstract][Full Text] [Related]
14. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
Sheridan W; Menchaca D
Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
Farese AM; MacVittie TJ; Roskos L; Stead RB
Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
[TBL] [Abstract][Full Text] [Related]
16. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Bennett CL; Evens AM; Andritsos LA; Balasubramanian L; Mai M; Fisher MJ; Kuzel TM; Angelotta C; McKoy JM; Vose JM; Bierman PJ; Kuter DJ; Trifilio SM; Devine SM; Tallman MS
Br J Haematol; 2006 Dec; 135(5):642-50. PubMed ID: 17054431
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
[TBL] [Abstract][Full Text] [Related]
18. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.
Snyder E; Perrotta P; Rinder H; Baril L; Nichol J; Gilligan D
Transfusion; 1999 Mar; 39(3):258-64. PubMed ID: 10204587
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
